Molecular targeted therapy of oral squamous cell carcinoma targeting HSP90

2015 ◽  
Vol 44 ◽  
pp. e271-e272
Author(s):  
T. Onda ◽  
K. Hayashi ◽  
S. Sekikawa ◽  
R. Ohta ◽  
Y. Watabe ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Targeted Therapy ◽  
Oral Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Molecular Targeted Therapy

scholarly journals Clinical Development of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma

2019 ◽  
Vol 3 (4) ◽  
Author(s):  
Paul Gougis ◽  
Camille Moreau Bachelard ◽  
Maud Kamal ◽  
Hui K Gan ◽  
Edith Borcoman ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Targeted Therapy ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Cancer Biology ◽  
Molecular Targeted Therapy ◽  
Locally Advanced ◽  
Clinical Development ◽  
Neck Squamous Cell Carcinoma

Abstract A better understanding of cancer biology has led to the development of molecular targeted therapy, which has dramatically improved the outcome of some cancer patients, especially when a biomarker of efficacy has been used for patients’ selection. In head and neck oncology, cetuximab that targets epidermal growth factor receptor is the only targeted therapy that demonstrated a survival benefit, both in the recurrent and in the locally advanced settings, yet without prior patients’ selection. We herein review the clinical development of targeted therapy in head and neck squamous cell carcinoma in light of the molecular landscape and give insights in on how innovative clinical trial designs may speed up biomarker discovery and deployment of new molecular targeted therapies. Given the recent approval of immune checkpoint inhibitors targeting programmed cell death-1 in head and neck squamous cell carcinoma, it remains to be determined how targeted therapy will be incorporated into a global drug development strategy that will inevitably incorporate immunotherapy.

scholarly journals Current Trends and Future Prospects of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma

2020 ◽  
Vol 22 (1) ◽  
pp. 240
Author(s):  
Naoya Kitamura ◽  
Shinya Sento ◽  
Yasumasa Yoshizawa ◽  
Eri Sasabe ◽  
Yasusei Kudo ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Targeted Therapy ◽  
Drug Therapy ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Molecular Targeted Therapy ◽  
Future Prospects ◽  
Current Trends ◽  
Anti Cancer

In recent years, advances in drug therapy for head and neck squamous cell carcinoma (HNSCC) have progressed rapidly. In addition to cytotoxic anti-cancer agents such as platinum-based drug (cisplatin and carboplatin) and taxane-based drugs (docetaxel and paclitaxel), epidermal growth factor receptor-tyrosine kinase inhibitors (cetuximab) and immune checkpoint inhibitors such as anti-programmed cell death-1 (PD-1) antibodies (nivolumab and pembrolizumab) have come to be used. The importance of anti-cancer drug therapy is increasing year by year. Therefore, we summarize clinical trials of molecular targeted therapy and biomarkers in HNSCC from previous studies. Here we show the current trends and future prospects of molecular targeted therapy in HNSCC.

scholarly journals Progress of molecular targeted therapy for head and neck cancer in clinical aspects

2021 ◽  
Vol 2 (1) ◽  
Author(s):  
Kenji Nakano
Keyword(s):  
Squamous Cell Carcinoma ◽  
Clinical Trials ◽  
Head And Neck Cancer ◽  
Targeted Therapy ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Cancer Patients ◽  
Neck Cancer ◽  
Squamous Cell ◽  
Molecular Targeted Therapy

AbstractSince the body’s head and neck area affects many functions such as breathing, swallowing, and speaking, systemic treatments to head and neck cancer patients are important not only for survival but also for preserving functions and quality of life. With the progress that has been made in molecular targeted therapy, anti-EGFR antibody (cetuximab) and immune checkpoint inhibitors (nivolumab, pembrolizumab) have provided survival benefits to head and neck cancer patients and are approved for clinical practice. Clinical trials incorporating these new drugs for patients with locally advanced head/neck cancers are underway. However, the existing clinical evidence regarding molecular targeted drugs for head and neck cancers is based mostly on clinical trials allocated to squamous cell carcinoma patients. New targeted therapies for non-squamous cell carcinoma patients were recently reported, e.g., tyrosine kinase inhibitors for the treatment of thyroid cancers and HER2-targeted therapy for salivary gland cancers. With the goal of improving local control, molecular targeted treatment strategies as salvage local therapy are being investigated, including boron neutron capture therapy (BNCT) and near-infrared photoimmunotherapy (NIR-PIT). Herein the history and landscape of molecular targeted therapy for head and neck cancers are summarized and reviewed.

scholarly journals Utilizing feline oral squamous cell carcinoma patients to develop NQO1-targeted therapy

Neoplasia ◽  
2021 ◽  
Vol 23 (8) ◽  
pp. 811-822
Author(s):  
Alycen P. Lundberg ◽  
Matthew W. Boudreau ◽  
Kim A. Selting ◽  
Lindsay E. Chatkewitz ◽  
Jonathan Samuelson ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Targeted Therapy ◽  
Oral Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell

scholarly journals Study on the targeted therapy of oral squamous cell carcinoma with a plasmid expressing PE38KDEL toxin under control of the SERPINB3 promoter

2020 ◽  
Vol 9 (6) ◽  
pp. 2213-2222
Author(s):  
Jiang Wu ◽  
Qiong Guo ◽  
Guoliang Zhang ◽  
Liying Zhao ◽  
Yvguang Lv ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Targeted Therapy ◽  
Oral Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell
Sign in / Sign up

Export Citation Format

Share Document